

FILED

2012 NOV 15 AM 11:31
CLERK U.S. DISTRICT COURT
CENTRAL DIST. OF CALIF.
SANTA ANA

1 Tyler J. Woods (State Bar No. 232464)
twoods@trialnewport.com
2 Richard H. Hikida (State Bar No. 196149)
rhikida@trialnewport.com
3 Scott J. Ferrell (State Bar No. 202091)
sferrell@trialnewport.com
4 **NEWPORT TRIAL GROUP**
A Professional Corporation
5 895 Dove Street, Suite 425
Newport Beach, CA 92660
6 Tel: (949) 706-6464
Fax: (949) 706-6469

7 Attorneys for Plaintiff
8

9 **UNITED STATES DISTRICT COURT**
10 **CENTRAL DISTRICT OF CALIFORNIA**

11 **THE TAWNSAURA GROUP, LLC,**

12 Plaintiff,

13 vs.

14 **USP LABS, LLC,**

15 Defendant

Case No. **SACV 12 - 02003 DOC (JPRx)**

**COMPLAINT FOR PATENT
INFRINGEMENT**

JURY TRIAL DEMANDED

1 Plaintiff The Tawnsaura Group, LLC (“Plaintiff”) hereby alleges for its
2 Complaint against USP Labs, LLC (“Defendant”), on personal knowledge as to its own
3 activities and on information and belief as to the activities of others, as follows:

4 **I. THE PARTIES**

5 1. Plaintiff is a limited liability company organized and existing under the
6 laws of Nevada, with a registered office at 50 West Liberty Street, Suite 1100, Reno,
7 Nevada 89501.

8 2. Plaintiff is the owner and assignee of United States Patent No. 5,874,471
9 (“the ‘471 patent”) titled “Orthomolecular Medical Use of L-Citrulline for
10 Vasoprotection, Relaxative Smooth Muscle Tone and Cell Protection,” and United
11 States Patent No. 6,028,107 (“the ‘107 patent”) titled “Orthomolecular Medical Use of
12 L-Citrulline for Vasoprotection, Relaxative Smooth Muscle Tone and Cell Protection,”
13 and Plaintiff licenses the ‘471 patent and the ‘107 patent to more than one third-party
14 and is in negotiations to license the patents to numerous other parties.

15 3. Upon information and belief, Defendant USP Labs, LLC is a company
16 organized and existing under the laws of Texas with a principal place of business at
17 10761 King William Drive in Dallas, Texas, 75220.

18 **II. JURISDICTION AND VENUE**

19 4. This is an action for patent infringement arising under the patent laws of
20 the United States, Title 35 of the United States Code. Accordingly, this Court has
21 subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338, and 1367.

22 5. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400.

23 6. This Court has personal jurisdiction over Defendant. Defendant, directly
24 or through intermediaries (including distributors, retailers, and others), ships,
25 distributes, offers for sale, sells, and advertises its nutritional supplement products in
26 the United States, the State of California, and the Central District of California,
27 including the products sold under the “Jack3d Micro” line of products. Defendant has
28

1 purposefully and voluntarily placed these products into the stream of commerce with
2 the expectation that they will be purchased in the Central District of California.

3 **III. THE DEFENDANT'S INFRINGING PRODUCTS**

4 7. The label and/or advertisements for Defendant's Jack3d Micro products
5 state that they contain, inter alia, the ingredient "L-Citrulline" as part of an "eNOS
6 [Endothelial Nitric Oxide Synthase] Super Performance System," as well as the
7 ingredient "Vitamin C (Ascorbic Acid)."

8 8. Advertisements for Jack3d Micro products further state, by way of
9 example, and particularly at <http://www.jack3dmicro.org/buy>, that: "L-citrulline, or
10 more commonly known as citrulline is Jack3d Micro's primary pump ingredient. A
11 powerful nitric oxide enhancer, citrulline promotes a healthier blood flow and improves
12 nutrient delivery and transport. Citrulline is best known for improving the
13 cardiovascular system by relaxing the blood vessels and optimizing the amount of
14 oxygen that is distributed towards the muscles...."

15 9. As set forth herein, these products infringe the claimed methods of the
16 '471 patent and the '107 patent, and are therefore referred to herein as "the products
17 that infringe the claimed methods."

18 **IV. THE DEFENDANT'S INFRINGEMENTS**

19 10. Defendant's employees, agents, representatives and other persons
20 sponsored by or who endorse Defendant and Defendant's products in advertising and
21 marketing activities, have taken, used, and orally administered the products that
22 infringe the claimed methods which have the effect, without limitation, of increasing
23 the plasma level of arginine in the persons taking the products from a low or normal
24 fasting level to a level which is up to three times an average overnight fasting level and
25 increasing the plasma concentration of arginine in the persons taking the products from
26 a low or normal fasting concentration to a level which is up to three times an average
27 overnight fasting arginine level of about 90 mu.mole per liter of plasma. These persons
28 included persons who, without limitation, were in good health, were in a condition of

1 increased or continuing brain or neural activities, or were in a condition of increased or
2 continuing muscular activities. Defendant has encouraged and/or is aware of these
3 persons' oral administration of the products that infringe the claimed methods for these
4 purposes, and these persons are acting under Defendant's direction and control.
5 Therefore, Defendant practices the methods as set forth in the '471 patent and the '107
6 patent and is a direct infringer of the patents.

7 11. End-users of Defendant's products that infringe the claimed methods are
8 also direct infringers of the '471 patent and the '107 patent, because they have taken,
9 used, and orally administered the products that infringe the claimed methods which
10 have the effect, without limitation, of increasing the plasma level of arginine in the
11 persons taking the products from a low or normal fasting level to a level which is up to
12 three times an average overnight fasting level and/or increasing the plasma
13 concentration of arginine in the persons taking the products from a low or normal
14 fasting concentration to a level which is up to three times an average overnight fasting
15 arginine level of about 90 μ mole per liter of plasma. These persons included persons
16 who, without limitation, were in good health, were in a condition of increased or
17 continuing brain or neural activities, or were in a condition of increased or continuing
18 muscular activities. Therefore, they practice the methods as set forth in the '471 patent
19 and the '107 patent.

20 12. By way of example and without limitation, an end-user of Jack3d Micro
21 identified as "George" posted a review on [http://www.fitflex.com/usplabs-jack3d-](http://www.fitflex.com/usplabs-jack3d-micro-review.html)
22 [micro-review.html](http://www.fitflex.com/usplabs-jack3d-micro-review.html) regarding his use of the product, indicating, "I've never had such as
23 sweet pump with every single workout." This is just one of many end-users of the
24 infringing products who has practiced the methods as set forth in the '471 patent and
25 the '107 patent and is a direct infringer of the patents.

26 13. Plaintiff believes facts to be ascertained during discovery in this matter
27 will demonstrate that Defendant's labels and advertising for the products that infringe
28 the claimed methods explain the elements and essential elements of the methods

1 disclosed in the '471 patent and the '107 patent to end-users and encourage, urge, and
2 induce the products' end-users to purchase and orally administer the products to
3 practice those methods, and end-users do practice those methods, and that Defendant
4 has therefore specifically intended to cause these end-users to directly infringe the
5 claimed methods of the patents, and has urged them to do so. Plaintiff intends to amend
6 this complaint at the appropriate time to include more specific allegations pertaining to
7 these facts.

8 14. Defendant's products that infringe the claimed methods are not suitable for
9 non-infringing uses, and none of Defendant's labels or advertisements for the products
10 disclose any uses for the products nor for the citrulline in those products that do not
11 infringe upon the methods disclosed in the '471 patent and the '107 patent. The
12 inclusion of the citrulline content in the products are, in fact, material to practicing the
13 methods disclosed in the '471 patent and the '107 patent.

14 15. Plaintiff believes facts to be ascertained during discovery in this matter
15 will demonstrate that Defendant has knowledge that its products that infringe the
16 claimed methods are especially adapted by end-users of the products for the practicing
17 of the methods disclosed in the '471 patent and '107 patent, and, indeed, Defendant
18 encourages, urges, and induces the products' end-users to purchase and orally
19 administer the products to practice those methods, and has done so in the past. Plaintiff
20 intends to amend this complaint at the appropriate time to include more specific
21 allegations pertaining to these facts.

22 16. Plaintiff believes facts to be ascertained during discovery in this matter
23 will demonstrate that Defendant has intentionally and knowingly induced, encouraged,
24 and urged end-users of the products that infringe the claimed methods to purchase and
25 orally administer the products for the purpose, without limitation, of increasing the
26 plasma level of arginine in the persons taking the products from a low or normal fasting
27 level to a level which is up to three times an average overnight fasting level and
28 increasing the plasma concentration of arginine in the persons taking the products from

1 a low or normal fasting concentration to a level which is up to three times an average
2 overnight fasting arginine level of about 90 μ mole per liter of plasma, including by
3 end-users who, without limitation, were in good health, were in a condition of increased
4 or continuing brain or neural activities, or were in a condition of increased or
5 continuing muscular activities. Plaintiff intends to amend this complaint at the
6 appropriate time to include more specific allegations pertaining to these facts.

7 17. Plaintiff believes facts to be ascertained during discovery in this matter
8 will demonstrate that Defendant had actual, first-hand knowledge of the '471 patent and
9 the '107 patent as early as the time Defendant launched each of the products that
10 infringe the claimed methods in the marketplace. By way of example and without
11 limitation, Plaintiff believes such facts to be ascertained will include the fact that
12 Defendant employs and engages sophisticated, experienced legal counsel with expertise
13 in patent law, and that Defendant, through its counsel, conducts or should conduct due
14 diligence on the potential for Defendant's products to infringe on patents and knew or
15 should have known that the products that infringe the claimed methods actually infringe
16 or could infringe on the '471 patent and '107 patent, but Defendant decided to infringe
17 the patents anyway or ignored the risk of infringement. By way of further example and
18 without limitation, Plaintiff believes such facts to be ascertained will include the fact
19 that Defendant became aware of the '471 patent and '107 patent following the filing of
20 lawsuits by Plaintiff against Defendant's competitors arising out of infringements by
21 those competitors of the patents. Plaintiff intends to amend this complaint at the
22 appropriate time to include more specific allegations pertaining to these facts.

23 18. In the alternative, Plaintiff believes facts to be ascertained during
24 discovery in this matter will demonstrate that Defendant subjectively believed at the
25 time Defendant launched each of the products that infringe the claimed methods in the
26 marketplace that there is or was a high probability of the fact that patents existed that
27 covered the use of citrulline as in the products and that Defendant took deliberate
28 actions to avoid confirming that fact, including not conducting due diligence as to

1 potential patent infringements, and that Defendant therefore willfully blinded itself to
2 the infringing nature of its sales of the products that infringe the claimed methods.
3 Plaintiff intends to amend this complaint at the appropriate time to include more
4 specific allegations pertaining to these facts.

5 19. At a minimum, Defendant will become aware of the '471 patent and the
6 '107 patent at the time of the filing and service of this Complaint, yet Defendant will
7 likely not cease its own direct infringement, nor what Plaintiff believes is Defendant's
8 indirect infringement by contributory infringement or inducement of infringements by
9 end-users, despite such knowledge. Plaintiff intends to amend this complaint at the
10 appropriate time to include more specific allegations pertaining to these post-filing
11 activities, based on facts to be ascertained during discovery in this matter.

12 20. The earliest exact date Defendant obtained knowledge of the '471 patent
13 and the '107 patent is within the exclusive possession and control of Defendant.
14 However, Plaintiff believes facts to be ascertained during discovery in this matter will
15 demonstrate that Defendant specifically induces end-users to use its products, and
16 particularly the citrulline component in the products, to enhance their nitric oxide
17 levels, promote blood flow, relax blood vessels, and optimize the amount of oxygen
18 distributed toward their muscles, and Defendant knows and intends that end-users
19 achieve those objectives by practicing the methods as set forth in the '471 and '107
20 patents. Plaintiff believes facts to be ascertained during discovery in this matter will
21 demonstrate that this is why Defendant includes citrulline in its products – for the
22 purposes of improving of the health of end-users to increase the plasma level of
23 arginine in end-users to a level from a low or normal fasting level to a level which is up
24 to three times an average overnight fasting level, and improving the health of end-users
25 to increase the plasma concentration of arginine in the subject to a level from a low or
26 normal fasting concentration to a level which is up to three times an average overnight
27 fasting arginine level of about 90 μ mole per liter of plasma – and Defendant knows
28 that end-users purchase and ingest the products, and particularly the citrulline content

1 of the products, for those purposes. Plaintiff intends to amend this complaint at the
2 appropriate time to include more specific allegations pertaining to these facts.

3 **V. FIRST CAUSE OF ACTION**

4 **Infringement of U.S. Patent No. 5,874,471**

5 21. Plaintiff repeats and re-alleges the allegations of the foregoing paragraphs
6 of this Complaint as if fully set forth herein.

7 22. Defendant has in the past and still is literally and directly infringing or
8 directly infringing under the doctrine of equivalents one or more claims of the '471
9 patent by making, using, selling, and offering for sale nutritional supplements
10 embodying the patented invention, and will continue to do so unless enjoined by this
11 Court.

12 23. The claims of the '471 patent infringed by Defendant include claims 1, 2,
13 20, 21, and 28.

14 24. Examples of Defendant's direct infringement includes, without limitation,
15 the fact that Defendant's employees, agents, representatives and other persons
16 sponsored by or who endorse Defendant and Defendant's products in advertising and
17 marketing activities, have taken, used, and orally administered the products that
18 infringe the claimed methods which have the effect, without limitation, of increasing
19 the plasma level of arginine in the persons taking the products from a low or normal
20 fasting level to a level which is up to three times an average overnight fasting level.
21 These persons included persons who, without limitation, were in good health, were in a
22 condition of increased or continuing brain or neural activities, or were in a condition of
23 increased or continuing muscular activities. Defendant has encouraged and/or is aware
24 of these persons' oral administration of the products that infringe the claimed methods
25 for these purposes, these persons are acting under Defendant's direction and control,
26 and therefore Defendant is directly practicing the methods set forth in the '471 patent.

27 25. Plaintiff believes facts to be ascertained during discovery in this matter
28 will demonstrate that Defendant is also literally and indirectly or indirectly infringing

1 under the doctrine of equivalents, through contributory and/or induced infringement,
2 one or more claims of the '471 patent. Plaintiff intends to amend this First Cause of
3 Action at the appropriate time once more specific facts pertaining to Defendant's acts
4 of indirect infringement are ascertained.

5 26. Defendant's activities have been without express or implied license by
6 Plaintiff.

7 27. Plaintiff believes facts to be ascertained during discovery in this matter
8 will demonstrate that the infringement by Defendant has been and continues to be
9 willful, and Plaintiff intends to amend this First Cause of Action at the appropriate time
10 once more specific facts pertaining to Defendant's willful acts of infringement are
11 ascertained.

12 28. As a result of Defendant's acts of infringement, Plaintiff has suffered and
13 will continue to suffer damages in an amount to be proved at trial.

14 29. As a result of Defendant's acts of infringement, Plaintiff has been and will
15 continue to be irreparably harmed by Defendant's infringements, which will continue
16 unless Defendant is enjoined by this Court.

17 30. Plaintiff believes facts to be ascertained during discovery in this matter
18 will demonstrate that Defendant's past infringement and/or continuing infringement has
19 been deliberate and willful, and that this case is therefore an exceptional case, which
20 warrants an award of treble damages and attorneys' fees in accordance with 35 U.S.C. §
21 285. Plaintiff intends to amend this First Cause of Action at the appropriate time once
22 more specific facts pertaining to Defendant's deliberate and willful acts of infringement
23 are ascertained.

24 VI. SECOND CAUSE OF ACTION

25 Infringement of U.S. Patent No. 6,028,107

26 31. Plaintiff repeats and re-alleges the allegations of the foregoing paragraphs
27 of this Complaint as if fully set forth herein.
28

1 32. Defendant has in the past and still is literally and directly infringing or
2 directly infringing under the doctrine of equivalents one or more claims of the '107
3 patent by making, using, selling, and offering for sale nutritional supplements
4 embodying the patented invention, and will continue to do so unless enjoined by this
5 Court.

6 33. The claims of the '107 patent infringed by Defendant include claims 1, 2,
7 15, 16, and 19.

8 34. Plaintiff believes facts to be ascertained during discovery in this matter
9 will demonstrate that Defendant is also literally and indirectly or indirectly infringing
10 under the doctrine of equivalents, through contributory and/or induced infringement,
11 one or more claims of the '107 patent. Plaintiff intends to amend this Second Cause of
12 Action at the appropriate time once more specific facts pertaining to Defendant's acts
13 of indirect infringement are ascertained.

14 35. Examples of Defendant's direct infringement includes, without limitation,
15 the fact that Defendant's employees, agents, representatives and other persons
16 sponsored by or who endorse Defendant and Defendant's products in advertising and
17 marketing activities, have taken, used, and orally administered the products that
18 infringe the claimed methods which have the effect, without limitation, of increasing
19 the plasma concentration of arginine in the persons taking the products from a low or
20 normal fasting concentration to a level which is up to three times an average overnight
21 fasting arginine level of about 90 μ mole per liter of plasma. These persons included
22 persons who, without limitation, were in good health, were in a condition of increased
23 or continuing brain or neural activities, or were in a condition of increased or
24 continuing muscular activities. Defendant has encouraged and/or is aware of these
25 persons' oral administration of the products that infringe the claimed methods for these
26 purposes, these persons are acting under Defendant's direction and control, and
27 therefore Defendant is directly practicing the methods set forth in the '107 patent.
28

36. Defendant's activities have been without express or implied license by Plaintiff.

37. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that the infringement by Defendant has been and continues to be willful, and Plaintiff intends to amend this Second Cause of Action at the appropriate time once more specific facts pertaining to Defendant's willful acts of infringement are ascertained.

38. As a result of Defendant's acts of infringement, Plaintiff has suffered and will continue to suffer damages in an amount to be proved at trial.

39. As a result of Defendant's acts of infringement, Plaintiff has been and will continue to be irreparably harmed by Defendant's infringements, which will continue unless Defendant is enjoined by this Court.

40. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant's past infringement and/or continuing infringement has been deliberate and willful, and that this case is therefore an exceptional case, which warrants an award of treble damages and attorneys' fees in accordance with 35 U.S.C. § 285. Plaintiff intends to amend this Second Cause of Action at the appropriate time once more specific facts pertaining to Defendant's deliberate and willful acts of infringement are ascertained.

VII. PRAYER FOR RELIEF

WHEREFORE, Plaintiff prays for entry of judgment against Defendant as follows:

1. A declaration that Defendant has infringed the ‘471 patent and the ‘107 patent under 35 U.S.C. §§ 271 *et seq.*;

2. That injunctions, preliminary and permanent, be issued by this Court restraining Defendant, its respective officers, agents, servants, directors, and employees, and all persons in active concert or participation with each, from directly infringing the '471 patent and the '107 patent;

1 3. That Defendant be required to provide to Plaintiff an accounting of all
2 gains, profits, and advantages derived by Defendant's infringement of the '471 patent
3 and the '107 patent, and that Plaintiff be awarded damages adequate to compensate
4 Plaintiff for the wrongful infringing acts by Defendant, in accordance with 35 U.S.C. §
5 284;

6 4. That, at the appropriate time after more specific facts pertaining to
7 Defendant's acts of indirect, willful, and deliberate infringement are ascertained and
8 this Complaint is amended to include such facts: (a) injunctions, preliminary and
9 permanent, be issued by this Court restraining Defendant, its respective officers, agents,
10 servants, directors, and employees, and all persons in active concert or participation
11 with each, from indirectly infringing the '471 patent and the '107 patent; (b) Defendant
12 be required to provide to Plaintiff an accounting of all gains, profits, and advantages
13 derived by Defendant's indirect infringement of the '471 patent and the '107 patent; (c)
14 Plaintiff be awarded damages adequate to compensate Plaintiff for the wrongful
15 infringing acts by Defendant, in accordance with 35 U.S.C. § 284; and (d) the damages
16 awarded to Plaintiff with regard to the '471 patent and the '107 patent be increased up
17 to three times, in view of Defendant's willful infringement, in accordance with 35
18 U.S.C. § 284;

19 5. That, at the appropriate time after more specific facts pertaining to
20 Defendant's acts of willful and deliberate infringement are ascertained and this
21 Complaint is amended to include such facts, this case be declared to be exceptional in
22 favor of Plaintiff under 35 U.S.C. § 285, and that Plaintiff be awarded its reasonable
23 attorneys' fees and other expenses incurred in connection with this action;

24 6. That Plaintiff be awarded its interest and costs of suit incurred in this
25 action;

26 7. Compensatory damages;


27 8. Punitive damages; and

28 9. That Plaintiff be awarded such other and further relief as this Court may

1 deem just and proper.

2
3 Respectfully submitted,
4 NEWPORT TRIAL GROUP
5 A Professional Corporation

6 Dated: November 14, 2012

7 
8 By: Tyler J. Woods
9 Attorneys for Plaintiff
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


DEMAND FOR JURY TRIAL

Pursuant to Federal Rule of Civil Procedure 38(b), Plaintiff hereby demands a jury trial for all issues in this case that properly are subject to a jury trial.

Respectfully submitted,

NEWPORT TRIAL GROUP
A Professional Corporation

Dated: November 14, 2012


By: Tyler J. Woods
Attorneys for Plaintiff

**UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA**

NOTICE OF ASSIGNMENT TO UNITED STATES MAGISTRATE JUDGE FOR DISCOVERY

This case has been assigned to District Judge David O. Carter and the assigned discovery Magistrate Judge is Jean P. Rosenbluth.

The case number on all documents filed with the Court should read as follows:

SACV12- 2003 DOC (JPRx)

Pursuant to General Order 05-07 of the United States District Court for the Central District of California, the Magistrate Judge has been designated to hear discovery related motions.

All discovery related motions should be noticed on the calendar of the Magistrate Judge

=====

NOTICE TO COUNSEL

A copy of this notice must be served with the summons and complaint on all defendants (if a removal action is filed, a copy of this notice must be served on all plaintiffs).

Subsequent documents must be filed at the following location:

☐ **Western Division**
312 N. Spring St., Rm. G-8
Los Angeles, CA 90012

☐ **Southern Division**
411 West Fourth St., Rm. 1-053
Santa Ana, CA 92701-4516

☐ **Eastern Division**
3470 Twelfth St., Rm. 134
Riverside, CA 92501

Failure to file at the proper location will result in your documents being returned to you.

Name & Address: NEWPORT TRIAL GROUP
 Tyler J. Woods (State Bar No. 232464)
 Richard H. Hikida (State Bar No. 196149)
 Scott J. Ferrell (State Bar No. 202091)
 895 Dove Street, Ste 425, Newport Beach, CA 92660

UNITED STATES DISTRICT COURT
 CENTRAL DISTRICT OF CALIFORNIA

THE TAWNSAURA GROUP, LLC,

PLAINTIFF(S)

v.

USP LABS, LLC

DEFENDANT(S).

CASE NUMBER

SACV 12 - 02003 DOC (JPRx)

SUMMONS

TO: DEFENDANT(S):

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it), you must serve on the plaintiff an answer to the attached ☒ complaint ☐ _____ amended complaint ☐ counterclaim ☐ cross-claim or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff's attorney, Newport Trial Group _____, whose address is 895 Dove Street, Suite 425, Newport Beach, CA 92660 _____. If you fail to do so, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

Clerk, U.S. District Court

Dated: 11/15/2012

By: Denise VO
 Deputy Clerk

(Seal of the Court)

[Use 60 days if the defendant is the United States or a United States agency, or is an officer or employee of the United States. Allowed 60 days by Rule 12(a)(3)].

Name & Address: NEWPORT TRIAL GROUP
 Tyler J. Woods (State Bar No. 232464)
 Richard H. Hikida (State Bar No. 196149)
 Scott J. Ferrell (State Bar No. 202091)
 895 Dove Street, Ste 425, Newport Beach, CA 92660

UNITED STATES DISTRICT COURT
 CENTRAL DISTRICT OF CALIFORNIA

THE TAWNSAURA GROUP, LLC,

PLAINTIFF(S)

v.

USP LABS, LLC

DEFENDANT(S).

CASE NUMBER

SACV 12 - 02003 DOC (JPRx)

SUMMONS

TO: DEFENDANT(S):

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it), you must serve on the plaintiff an answer to the attached ☒ complaint ☐ amended complaint ☐ counterclaim ☐ cross-claim or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff's attorney, Newport Trial Group, whose address is 895 Dove Street, Suite 425, Newport Beach, CA 92660. If you fail to do so, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

Clerk, U.S. District Court

Dated: 11/15/2012

By: DNISE VO
 Deputy Clerk



(Seal of the Court)

[Use 60 days if the defendant is the United States or a United States agency, or is an officer or employee of the United States. Allowed 60 days by Rule 12(a)(3)].

**UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA
CIVIL COVER SHEET**

I (a) PLAINTIFFS (Check box if you are representing yourself <input type="checkbox"/>) THE TAWNSAURA GROUP, LLC,	DEFENDANTS USP LABS, LLC
(b) Attorneys (Firm Name, Address and Telephone Number. If you are representing yourself, provide same.) NEWPORT TRIAL GROUP, 895 Dove Street, Suite 425, Newport Beach, CA 92660 Tel; (949) 706-6464 Fax (949)706-6469	Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an X in one box only.) <input type="checkbox"/> 1 U.S. Government Plaintiff <input type="checkbox"/> 3 Federal Question (U.S. Government Not a Party) <input type="checkbox"/> 2 U.S. Government Defendant <input checked="" type="checkbox"/> 4 Diversity (Indicate Citizenship of Parties in Item III)	III. CITIZENSHIP OF PRINCIPAL PARTIES - For Diversity Cases Only (Place an X in one box for plaintiff and one for defendant.) <table style="width:100%;"> <tr> <td style="width:40%;">Citizen of This State</td> <td style="width:10%;">PTF <input type="checkbox"/> 1</td> <td style="width:10%;">DEF <input type="checkbox"/> 1</td> <td style="width:30%;">Incorporated or Principal Place of Business in this State</td> <td style="width:10%;">PTF <input type="checkbox"/> 4</td> <td style="width:10%;">DEF <input type="checkbox"/> 4</td> </tr> <tr> <td>Citizen of Another State</td> <td>PTF <input type="checkbox"/> 2</td> <td>DEF <input type="checkbox"/> 2</td> <td>Incorporated and Principal Place of Business in Another State</td> <td>PTF <input checked="" type="checkbox"/> 5</td> <td>DEF <input checked="" type="checkbox"/> 5</td> </tr> <tr> <td>Citizen or Subject of a Foreign Country</td> <td>PTF <input type="checkbox"/> 3</td> <td>DEF <input type="checkbox"/> 3</td> <td>Foreign Nation</td> <td>PTF <input type="checkbox"/> 6</td> <td>DEF <input type="checkbox"/> 6</td> </tr> </table>	Citizen of This State	PTF <input type="checkbox"/> 1	DEF <input type="checkbox"/> 1	Incorporated or Principal Place of Business in this State	PTF <input type="checkbox"/> 4	DEF <input type="checkbox"/> 4	Citizen of Another State	PTF <input type="checkbox"/> 2	DEF <input type="checkbox"/> 2	Incorporated and Principal Place of Business in Another State	PTF <input checked="" type="checkbox"/> 5	DEF <input checked="" type="checkbox"/> 5	Citizen or Subject of a Foreign Country	PTF <input type="checkbox"/> 3	DEF <input type="checkbox"/> 3	Foreign Nation	PTF <input type="checkbox"/> 6	DEF <input type="checkbox"/> 6
Citizen of This State	PTF <input type="checkbox"/> 1	DEF <input type="checkbox"/> 1	Incorporated or Principal Place of Business in this State	PTF <input type="checkbox"/> 4	DEF <input type="checkbox"/> 4														
Citizen of Another State	PTF <input type="checkbox"/> 2	DEF <input type="checkbox"/> 2	Incorporated and Principal Place of Business in Another State	PTF <input checked="" type="checkbox"/> 5	DEF <input checked="" type="checkbox"/> 5														
Citizen or Subject of a Foreign Country	PTF <input type="checkbox"/> 3	DEF <input type="checkbox"/> 3	Foreign Nation	PTF <input type="checkbox"/> 6	DEF <input type="checkbox"/> 6														

IV. ORIGIN (Place an X in one box only.)
☒ 1 Original Proceeding
 ☐ 2 Removed from State Court
 ☐ 3 Remanded from Appellate Court
 ☐ 4 Reinstated or Reopened
 ☐ 5 Transferred from another district (specify):
 ☐ 6 Multi-District Litigation
 ☐ 7 Appeal to District Judge from Magistrate Judge

V. REQUESTED IN COMPLAINT: **JURY DEMAND:** ☒ Yes ☐ No (Check 'Yes' only if demanded in complaint.)
CLASS ACTION under F.R.C.P. 23: ☐ Yes ☒ No **MONEY DEMANDED IN COMPLAINT:** \$ TBD

VI. CAUSE OF ACTION (Cite the U.S. Civil Statute under which you are filing and write a brief statement of cause. Do not cite jurisdictional statutes unless diversity.)
 35 USC §§271, et seq; 35 USC §§284; 35 USC §§285

VII. NATURE OF SUIT (Place an X in one box only.)

OTHER STATUTES <input type="checkbox"/> 400 State Reapportionment <input type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce/ICC Rates/etc. <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 810 Selective Service <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 875 Customer Challenge 12 USC 3410 <input type="checkbox"/> 890 Other Statutory Actions <input type="checkbox"/> 891 Agricultural Act <input type="checkbox"/> 892 Economic Stabilization Act <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 894 Energy Allocation Act <input type="checkbox"/> 895 Freedom of Info. Act <input type="checkbox"/> 900 Appeal of Fee Determination Under Equal Access to Justice <input type="checkbox"/> 950 Constitutionality of State Statutes	CONTRACT <input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loan (Excl. Veterans) <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise REAL PROPERTY <input type="checkbox"/> 210 Land Condemnation <input type="checkbox"/> 220 Foreclosure <input type="checkbox"/> 230 Rent Lease & Ejectment <input type="checkbox"/> 240 Torts to Land <input type="checkbox"/> 245 Tort Product Liability <input type="checkbox"/> 290 All Other Real Property	TORTS PERSONAL INJURY <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Fed. Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury <input type="checkbox"/> 362 Personal Injury-Med Malpractice <input type="checkbox"/> 365 Personal Injury-Product Liability <input type="checkbox"/> 368 Asbestos Personal Injury Product Liability IMMIGRATION <input type="checkbox"/> 462 Naturalization Application <input type="checkbox"/> 463 Habeas Corpus-Alien Detainee <input type="checkbox"/> 465 Other Immigration Actions	TORTS PERSONAL PROPERTY <input type="checkbox"/> 370 Other Fraud <input type="checkbox"/> 371 Truth in Lending <input type="checkbox"/> 380 Other Personal Property Damage <input type="checkbox"/> 385 Property Damage Product Liability BANKRUPTCY <input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 CIVIL RIGHTS <input type="checkbox"/> 441 Voting <input type="checkbox"/> 442 Employment <input type="checkbox"/> 443 Housing/Accommodations <input type="checkbox"/> 444 Welfare <input type="checkbox"/> 445 American with Disabilities - Employment <input type="checkbox"/> 446 American with Disabilities - Other <input type="checkbox"/> 440 Other Civil Rights	PRISONER PETITIONS <input type="checkbox"/> 510 Motions to Vacate Sentence <input type="checkbox"/> 530 Habeas Corpus General <input type="checkbox"/> 535 Death Penalty <input type="checkbox"/> 540 Mandamus/Other <input type="checkbox"/> 550 Civil Rights <input type="checkbox"/> 555 Prison Condition FORFEITURE / PENALTY <input type="checkbox"/> 610 Agriculture <input type="checkbox"/> 620 Other Food & Drug <input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 630 Liquor Laws <input type="checkbox"/> 640 R.R. & Truck <input type="checkbox"/> 650 Airline Regs <input type="checkbox"/> 660 Occupational Safety /Health <input type="checkbox"/> 690 Other	LABOR <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Mgmt. Relations <input type="checkbox"/> 730 Labor/Mgmt. Reporting & Disclosure Act <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Empl. Ret. Inc. Security Act PROPERTY RIGHTS <input type="checkbox"/> 820 Copyrights <input checked="" type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark SOCIAL SECURITY <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405(g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405(g)) FEDERAL TAX SUITS <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS-Third Party 26 USC 7609
---	--	--	---	--	--

FOR OFFICE USE ONLY: Case Number: **SACV 12 - 02003 DOC (JPRx)**

AFTER COMPLETING THE FRONT SIDE OF FORM CV-71, COMPLETE THE INFORMATION REQUESTED BELOW.

VIII(a). IDENTICAL CASES: Has this action been previously filed in this court and dismissed, remanded or closed? ☒ No ☐ Yes

If yes, list case number(s): _____

VIII(b). RELATED CASES: Have any cases been previously filed in this court that are related to the present case? ☒ No ☐ Yes

If yes, list case number(s): _____

Civil cases are deemed related if a previously filed case and the present case:

- (Check all boxes that apply) ☐ A. Arise from the same or closely related transactions, happenings, or events; or
☐ B. Call for determination of the same or substantially related or similar questions of law and fact; or
☐ C. For other reasons would entail substantial duplication of labor if heard by different judges; or
☐ D. Involve the same patent, trademark or copyright, and one of the factors identified above in a, b or c also is present.

IX. VENUE: (When completing the following information, use an additional sheet if necessary.)

- (a) List the County in this District; California County outside of this District; State if other than California; or Foreign Country, in which **EACH** named plaintiff resides.
☐ Check here if the government, its agencies or employees is a named plaintiff. If this box is checked, go to item (b).

County in this District:*	California County outside of this District; State, if other than California; or Foreign Country
	THE TAWNSAURA GROUP, LLC - Washoe County, Nevada

- (b) List the County in this District; California County outside of this District; State if other than California; or Foreign Country, in which **EACH** named defendant resides.
☐ Check here if the government, its agencies or employees is a named defendant. If this box is checked, go to item (c).

County in this District:*	California County outside of this District; State, if other than California; or Foreign Country
	USP LABS, LLC - Dallas County, TX

- (c) List the County in this District; California County outside of this District; State if other than California; or Foreign Country, in which **EACH** claim arose.
Note: In land condemnation cases, use the location of the tract of land involved.

County in this District:*	California County outside of this District; State, if other than California; or Foreign Country
Plaintiff's Claim - Orange County, CA	

* Los Angeles, Orange, San Bernardino, Riverside, Ventura, Santa Barbara, or San Luis Obispo Counties

Note: In land condemnation cases, use the location of the tract of land involved

X. SIGNATURE OF ATTORNEY (OR PRO PER): [Signature] Date November 14, 2012

Notice to Counsel/Parties: The CV-71 (JS-44) Civil Cover Sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law. This form, approved by the Judicial Conference of the United States in September 1974, is required pursuant to Local Rule 3-1 is not filed but is used by the Clerk of the Court for the purpose of statistics, venue and initiating the civil docket sheet. (For more detailed instructions, see separate instructions sheet.)

Key to Statistical codes relating to Social Security Cases:

Nature of Suit Code	Abbreviation	Substantive Statement of Cause of Action
861	HIA	All claims for health insurance benefits (Medicare) under Title 18, Part A, of the Social Security Act, as amended. Also, include claims by hospitals, skilled nursing facilities, etc., for certification as providers of services under the program. (42 U.S.C. 1935FF(b))
862	BL	All claims for "Black Lung" benefits under Title 4, Part B, of the Federal Coal Mine Health and Safety Act of 1969. (30 U.S.C. 923)
863	DIWC	All claims filed by insured workers for disability insurance benefits under Title 2 of the Social Security Act, as amended; plus all claims filed for child's insurance benefits based on disability. (42 U.S.C. 405(g))
863	DIWW	All claims filed for widows or widowers insurance benefits based on disability under Title 2 of the Social Security Act, as amended. (42 U.S.C. 405(g))
864	SSID	All claims for supplemental security income payments based upon disability filed under Title 16 of the Social Security Act, as amended.
865	RSI	All claims for retirement (old age) and survivors benefits under Title 2 of the Social Security Act, as amended. (42 U.S.C. (g))